PT  - JOURNAL ARTICLE
AU  - Sonya Park
AU  - Ashwin Singh Parihar
AU  - Lisa Bodei
AU  - Thomas A. Hope
AU  - Nadine Mallak
AU  - Corina Millo
AU  - Kalpna Prasad
AU  - Don Wilson
AU  - Katherine Zukotynski
AU  - Erik Mittra
TI  - Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
AID  - 10.2967/jnumed.120.251512
DP  - 2021 Oct 01
TA  - Journal of Nuclear Medicine
PG  - 1323--1329
VI  - 62
IP  - 10
4099  - http://jnm.snmjournals.org/content/62/10/1323.short
4100  - http://jnm.snmjournals.org/content/62/10/1323.full
SO  - J Nucl Med2021 Oct 01; 62
AB  - A new era of precision diagnostics and therapy for patients with neuroendocrine neoplasms began with the approval of somatostatin receptor (SSTR) radiopharmaceuticals for PET imaging followed by peptide receptor radionuclide therapy (PRRT). With the transition from SSTR-based γ-scintigraphy to PET, the higher sensitivity of the latter raised questions regarding the direct application of the planar scintigraphy–based Krenning score for PRRT eligibility. Also, to date, the role of SSTR PET in response assessment and predicting outcome remains under evaluation. In this comprehensive review article, we discuss the current role of SSTR PET in all aspects of neuroendocrine neoplasms, including its relation to conventional imaging, selection of patients for PRRT, and the current understanding of SSTR PET–based response assessment. We also provide a standardized reporting template for SSTR PET with a brief discussion.